Ariel Batiste

Associate

+1 202 408 4222 +1 202 408 4222
ariel.batiste@finnegan.com ariel.batiste@finnegan.com

901 New York Avenue, NW
Washington, DC 20001-4413

vCard

Show Ariel's work in

Ariel Batiste focuses on patent litigation in a variety of fields, with an emphasis on pharmaceutical and biological technologies. She has a technical background in neuroscience, neuroaffective disorders, and neurobiology.

Ariel worked as a summer associate at Finnegan, where she conducted legal and technical research for pharmaceutical clients in anticipation of litigation proceedings. She also assisted in getting a sentence reduction for a client as part of the firm’s robust pro bono practice.

While in law school, Ariel was a member of Howard’s Civil Rights Clinic. She did research and writing related to reforming the doctrine of qualified immunity. The clinic successfully represented its clients in a case Ariel was involved with when the U.S. Supreme Court denied certiorari, thereby upholding the US Court of Appeals for the Sixth Circuit’s favorable decision for the clients. See Campbell v. Cheatham Cnty. Sheriffs Dep’t, 47 F.4th 468 (6th Cir. 2022).

Ariel was president of the Huver I. Brown Trial Advocacy Moot Court Team. In 2023, Ariel and a teammate became the champions at the regional National Trial Competition. Furthermore, Ariel and the team made history by being the first students from a historically Black university to advance two teams to both the prestigious National Trial Competition and the American Association of Justice Trial Competition. Their performances catapulted Howard University School of Law’s trial team to one of the top ten in the country.

Et Cetera

Recipient, Professionalism Award, National Trial Competition, San Antonio, Texas, 2023.
President, Huver I. Brown Trial Advocacy Moot Court, 2022-2023.
Student attorney, Howard University School of Law Civil Rights Clinic, Washington, D.C., 2023.

Experience

In the Matter of Certain Semiconductor Devices and Products Containing the Same

Achieved a comprehensive victory for respondent Innoscience, a global leader in gallium nitride (GaN) power devices, in a high-profile patent dispute before the U.S. International Trade Commission (ITC). The ITC’s Final Determination confirms that Innoscience avoided all patent claims asserted by Infineon.

337‑TA‑1414, ITC, Judge Moore

In re Lumify

Successfully represented Bausch & Lomb and Eye Therapies in a Hatch-Waxman patent infringement litigation and parallel PTAB challenges concerning an ANDA for generic versions of over-the-counter Lumify® ocular drops. The cases settled favorably for our clients.

3:21-cv-16766, D.N.J., Judges Kirsch, Singh
IPR2022-00146, PTAB, Judges Hulse, New, Pollock
IPR2024-00467, PTAB, Judges Flax, Pollock, Yang
IPR2022-00142, PTAB, Judges Flax, Hulse, New, Pollock

Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof

Representing respondent Wacker Biotech GmbH in a rare section 337 ITC investigation involving drug products containing C-type natriuretic peptide variants.

337-TA-1447, ITC, Judge Cheney

Bausch & Lomb Incorporated; Bausch & Lomb Ireland Limited; Nicox, SA v. Gland Pharma Limited, et al.

Representing Bausch & Lomb in ANDA litigation involving Vyzulta® (latanoprostene bunod) eye drops for reduction of intraocular pressure (IOP) in patients suffering from glaucoma or ocular hypertension. Bausch & Lomb sought to protect the Vyzulta® franchise against challenges asserted by generic pharmaceutical manufacturers Dr. Reddy’s and Gland.

3:22-cv-04345, D.N.J., Judges Chesler, Kirsch, Shipp
3:23-cv-03463, D.N.J., Judge Kirsch